MorphoSys AG: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies- Results from the retrospective cohort analysis indicate significant

Related Keywords

Delaware ,United States ,Germany ,Boston ,Massachusetts ,Georgia ,Munich ,Bayern ,Atlanta ,American ,Grzegorz Nowakowski ,Peter Langmuir ,Nuwan Kurukulasuriya ,Practice Research Clinical Haematology ,Janssen Biotech Inc ,American Society Of Hematology Annual Meeting ,Xencor Inc ,Group Vice ,Drug Administration ,Global Head Of Medical Affairs ,Janssen Research Development ,Morphosys Us Inc ,Exchange Commission ,Meeting Of The Society Hematologic Oncology ,European Medicines Agency ,Hematologic Oncology ,American Society ,Hematology Annual Meeting ,Mayo Clinic ,Senior Vice President ,Global Head ,Medical Affairs ,Group Vice President ,Oncology Targeted Therapies ,Diffuse Largeb Cell Lymphoma ,National Comprehensive Cancer ,European Society ,Medical Oncology ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Medication Guide ,Patient Information ,Important Safety ,Janssen Research ,Janssen Biotech ,Morphosy Annual Report ,Practice Research ,Morphosys ,Incyte ,Nnounce ,Dditional ,Meal ,World ,Evidence ,Results ,Rom ,Ind2 ,Study ,Tafasitamab ,Monjuvi ,Combination ,Lenalidomide ,Treatment ,Relapsed ,Refractory ,Diffuse ,Barge ,Fell ,Gym ,